On-farm interventions to reduce the shedding of E. coli O157 by cattle, such as simple vaccination of cattle with Econiche, have the potential to reduce food and water contamination and the consequences associated with human infection with the deadly bacteria. Clinical trials conducted with Econiche have shown a significant reduction in the amount of E. coli shed in the manure of vaccinated cows.
"At today's Beef Value Chain Roundtable, I will be discussing the collaborative Canadian partnership that led to the development of Econiche," said Rick Culbert, President of Bioniche Food Safety. "I will also share information about the opportunity that vaccination of Canadian cattle represents beyond protecting public health, that is, a potential enhancement of the competitiveness of Canadian beef in export markets, where the vaccine is not yet available to producers."
About the Beef Value Chain Roundtable
The Beef Value Chain Roundtable was launched in January, 2003 and emerged as a key vehicle for helping ensure a coordinated response to Bovine Spongiform Encephalopathy (BSE) and as a key focal point for various working groups to engage with representatives of the entire beef value chain. Now more focused on long-term issues, membership on the beef roundtable includes ranchers, feedlot operators, processors, retail and food service representatives, feed suppliers and others.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Saf
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2009 PR Newswire.
All rights reserved